Is increased hepatitis C virus case‐finding combined with current or 8‐week to 12‐week direct‐acting antiviral therapy cost‐effective in UK prisons? A prevention benefit analysis-Reference-Cited by-同舟云学术

Is increased hepatitis C virus case‐finding combined with current or 8‐week to 12‐week direct‐acting antiviral therapy cost‐effective in UK prisons? A prevention benefit analysis

Published:2016-03-22 Issue:6 Volume:63 Page:1796-1808
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Martin Natasha K.¹²,Vickerman Peter²,Brew Iain F.³,Williamson Joan³,Miners Alec⁴,Irving William L.⁵,Saksena Sushma⁶,Hutchinson Sharon J.⁷,Mandal Sema⁸,O'Moore Eamonn⁸,Hickman Matthew²

Affiliation:

1. Division of Global Public HealthUniversity of California San DiegoSan Diego CA

2. School of Social and Community MedicineUniversity of BristolBristol UK

3. Leeds Community Healthcare NHS TrustLeeds UK

4. London School of Hygiene and Tropical MedicineLondon UK

5. University of NottinghamNottingham UK

6. County Durham and Darlington NHS TrustDarlington UK

7. Glasgow Caledonian UniversityGlasgow UK

8. Public Health EnglandLondon UK

Funder

Gilead Sciences

National Institute for Drug Abuse

University of California San Diego Center for AIDS Research

National Institutes of Health

National Institute for Health Research Health Protection Research Unit in Evaluation of Interventions

Health Protection Scotland

Scottish Government

National Institute for Health and Care Excellence

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.28497

Reference51 articles.

1. An evidence synthesis approach to estimating Hepatitis C Prevalence in England and Wales

2. Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir"

3. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons

4. MartinN MinersA VickermanP.Assessing the cost‐effectiveness of interventions aimed at promoting and offering hepatitis C testing in injecting drug users: an economic modelling report.https://www.nice.org.uk/guidance/ph43/evidence/economic‐modelling‐430273261;2012.

5. Health Protection Agency Colindale.Hepatitis C in the UK 2013.2013.https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/364074/Hepatitis_C_in_the_UK_2013.pdf.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost effectiveness of hepatitis C direct acting agents;Expert Review of Pharmacoeconomics & Outcomes Research;2024-05-03

2. Scale-up of direct-acting antiviral treatment in prisons is both cost-effective and key to HCV elimination;Open Forum Infectious Diseases;2023-12-18

3. Modeling the Health Economic Burden of Hepatitis C Virus Infection in Turkey: Cost-Effectiveness of Targeted Screening;The Turkish Journal of Gastroenterology;2023-10-03

4. High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results From the TraP Hep C Program—A Prospective Nationwide, Population-Based Study;Clinical Infectious Diseases;2022-04-19

5. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania;International Journal of Drug Policy;2022-01